

DAFTAR PUSTAKA

1. Lumb A, Thomas C. Nunn and Lumb's Applied Respiratory Physiology. 9th Edition. 2020;356–86.
2. Agusti A, Beasley R, Celli BR, Criner GJ, Halpin DMG, Varela MVL, et al. Pocket Guide to COPD: Diagnosis, Management and Prevention. Glob Initiat Chronic Obstr Lung Dis. 2023;7–35.
3. Kemenkes RI. Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia. Riskesdas. 2018;53(9):154–65.
4. Adeloeye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):11–45.
5. Currie GP, Legge JS. ABC of COPD: Diagnosis. Br Med J. 2006;332(5):1261–3.
6. Riley CM, Scirba FC. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA - J Am Med Assoc. 2019;321(8):745–6.
7. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):1–9.
8. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):2–11.
9. McLaughlin V V., McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114(13):1417–31.
10. Kim SHH, Park JHH, Lee JKK, Heo EY, Kim DK, Chung HS. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine (Baltimore). 2017 May;96(19):68–9.
11. Safitri Y, Siregar AA, Mukhtar Z. Hubungan Derajat Keparahan Penyakit Paru Obstruktif Kronik dengan Temuan Patologis Ekokardiografi di Rumah Sakit Umum Pusat Haji Adam Malik Medan. Univ Sumatera Utara Press. 2019;5–39.
12. GOLD. Global Initiative for Chronic Obstructive Lung. A Guid Heal Care Prof. 2023;1(3):5–205.
13. Agusti A, Beasley R, Celli BR, Dkk. Pocket Guide To COPD Diagnosis, Management, And Prevention". GOLD. 2023;15–115.
14. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet.

- 2017;389(10082):1931–40.
15. Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. *Ann Intern Med.* 2020;173(3):17–33.
 16. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. *Am J Respir Crit Care Med.* 1998;157(6):1770–8.
 17. Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, De-Torres JP, Cote C, et al. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. *Eur Respir J.* 2014;44(2):324–31.
 18. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. *Am J Respir Crit Care Med.* 2020;201(6):671–80.
 19. Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, et al. At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2018;197(12):1540–51.
 20. Duffy SP, Criner GJ. Chronic Obstructive Pulmonary Disease: Evaluation and Management. *Med Clin North Am.* 2019;103(3):453–61.
 21. A.Wisman B, Mardhiyah R, Tenda ED. Pendekatan Diagnostik dan Tatalaksana Penyakit Paru Obstruktif Kronik GOLD D: Sebuah Laporan Kasus. *Indones J Chest.* 2015;2(4):180–90.
 22. Nugraha I. Hubungan Derajat Berat Merokok Berdasarkan Indeks Brinkman Dengan Derajat Berat PPOK. *Indones One Search.* 2012;5–30.
 23. Subroto G, Arifianto, Retnaningsih D. Hubungan Derajat Berat Merokok (Indeks Brinkman) Dengan Derajat Obstruksi Pada Pasien PPOK Stabil Di RSPAW Salatiga. *J NERS Widya Husada.* 2021;2–9.
 24. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Vol. 370, *Lancet.* Elsevier B.V.; 2007. p. 765–73.
 25. Kistemaker LEMM, Oenema TA, Meurs H, Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: Perspectives on anticholinergic therapy in asthma and COPD. *Life Sci.* 2012;91(21–22):1126–33.
 26. MacNee W. Pathogenesis / Pathophysiology. *Arch Intern Med.* 2009;332(5):2–15.
 27. Bourdin A, Burgel PR, Chanez P, Garcia G, Perez T, Roche N. Recent advances in COPD: Pathophysiology, respiratory physiology and clinical aspects, including comorbidities. *Eur Respir Rev.* 2009;18(114):198–212.

28. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2012;186(10):982–8.
29. GINA committee. Global Strategy for Asthma Management and Prevention 2022 Update [Internet]. Global Initiative for Asthma. 2022. p. 2–225. Available from: <http://www.ginasthma.org>
30. Telo S, Kırkıl G, Kuluöztürk M, Balin M, Deveci F. Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease? *Clin Respir J*. 2018;12(4):1433–8.
31. Lareau SC, Fahy B, Meek P, Wang A. Chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med*. 2019;199(1):1–11.
32. Opitz I, Ulrich S. Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: Prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery. *J Thorac Dis*. 2018;10(2):2763–74.
33. Horn L, Lovly CM, Johnson DH. Dalam: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). 19th edition Harrison's principles of internal medicine. New York: McGraw- Hill Education. Neoplasms lung. 2015;506–23.
34. Unegbu C, Noje C, Coulson JD, Segal JB, Romer L. Pulmonary hypertension therapy and a systematic review of efficacy and safety of PDE-5 inhibitors. *Pediatrics*. 2017;139(3):2–25.
35. Oldroyd SH, Manek G, Sankari A, Bhardwaj A. Pulmonary Hypertension. 2022. 7–89 p.
36. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: A guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2019;5(3):11–24.
37. Daiyansyah S, Laksono S. Gambaran Ekokardiografi Jantung Bagian Kanan Pada Pasien Hipertensi Pulmonal. *Hum Care J*. 2022;7(2):290.
38. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. *Am J Respir Crit Care Med*. 2002;166(3):314–22.
39. Prins KW, Thenappan T. World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. *Cardiol Clin*. 2016;34(3):363–74.
40. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25):12–45.
41. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of

- echocardiography for pulmonary hypertension: A systematic review and meta-analysis. *Heart*. 2011;97(8):612–22.
42. Peinado VI, Gómez FP, Barberà JA, Roman A, Angels Montero M, Ramírez J, et al. Pulmonary vascular abnormalities in chronic obstructive pulmonary disease undergoing lung transplant. *J Hear Lung Transplant*. 2013;32(12):1262–9.
 43. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. *Eur Respir J*. 2002;19(4):632–8.
 44. Bunel V, Guyard A, Dauriat G, Danel C, Montani D, Gauvain C, et al. Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. *Chest*. 2019;156(1):33–44.
 45. Syso J, Machado R. Classification and pathophysiology of pulmonary hypertension. *Contin Ca. Biol Med*. 2018;15–35.
 46. McLaughlin V V., Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. A report of the american college of cardiology foundation task force on expert consensus documents and the american heart association. *Circulation*. 2009;119(16):2250–94.
 47. Zipes D, Libby P, Bonow R. Braunwald's Heart Disease. 8 ed Philadelphia Elsevier. 2019;167–90.
 48. Thenappan T, Prins KW. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. *Cardiol Clin*. 2017;34(3):363–74.
 49. Kent BD, Mitchell PD, Mcnicholas WT. Hypoxemia in patients with COPD: Cause, effects, and disease progression. *Int J COPD*. 2011;6(1):199–208.
 50. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. *Eur Respir J*. 2020;53(1):3–11.
 51. Sandek K, Bratel T, Hellström G, Lagerstrand L. Ventilation-perfusion inequality and carbon dioxide sensitivity in hypoxaemic chronic obstructive pulmonary disease (COPD) and effects of 6 months of long-term oxygen treatment (LTOT). *Clin Physiol*. 2001;21(5):584–93.
 52. Brusasco V. Clinical Tests of Respiratory Function. *Eur Respir Rev*. 2010 Mar;19(115):89–91.
 53. Wagner PD, Dantzker DR, Dueck R, Clausen JL, West JB. Ventilation-perfusion inequality in chronic obstructive pulmonary disease. *J Clin Invest*. 2007;59(2):203–16.
 54. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman Diagnosis dan Tatalaksana Hipertensi Pulmonal. 2021. 17–35 p.
 55. Stringham R, Shah NR. Pulmonary arterial hypertension: An update on

- diagnosis and treatment. *Am Fam Physician* [Internet]. 2010;82(4):370–7. Available from: <http://www.aafp.org/afp>.
56. Opotowsky AR. Clinical evaluation and management of pulmonary hypertension in the adult with congenital heart disease. *Circulation*. 2015;131(2):200–10.
 57. Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension. *J Am Coll Cardiol*. 2009;54(1):1–35.
 58. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: Epidemiology, significance, and management: Pulmonary vascular disease: The global perspective. *Chest*. 2010;137(6):39–51.
 59. Blanco I, Tura-Ceide O, Peinado VI, Barberà JA. Updated perspectives on pulmonary hypertension in COPD. *Int J COPD*. 2020;15:1315–24.
 60. Portillo K, Torralba Y, Blanco I, Burgos F, Rodriguez-Roisin R, Rios J, et al. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. *Int J COPD*. 2015;10(2):1313–20.
 61. Hilde JM, Skjørten I, Hansteen V, Melsom MN, Hisdal J, Humerfelt S, et al. Haemodynamic responses to exercise in patients with COPD. *Eur Respir J*. 2013;41(5):1031–41.
 62. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. *Eur Respir J*. 2008;32(5):1371–85.
 63. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of Cardiovascular Dysfunction In Chronic Obstructive Lung Disease. *N Engl J Med*. 2013;308(2):97–100.
 64. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. *Thorax*. 2011;36(10):752–8.
 65. Ni JR, Yan PJ, Liu SD, Hu Y, Yang KH, Song B, et al. Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: A systematic review and meta-analysis. *BMJ Open*. 2019;9(12):5–23.
 66. Roodpeyma S, Mojtahedzadeh S, Rafieyian S, Behbahani SR. Accuracy of electrocardiography and echocardiography in the assessment of pulmonary arterial hypertension in patients with congenital heart disease. *Iran Hear J*. 2015;15(4):20–5.
 67. Aguirre-Franco C, Torres-Duque CA, Salazar G, Casas A, Jaramillo C, Gonzalez-Garcia M. Prevalence of pulmonary hypertension in COPD patients living at high altitude. *Pulmonology*. 2022;2(2):1–7.
 68. Mao R, Liu Z, Zhao Y, Du C, Zhou J, Wang Q, et al. Stable Chronic Obstructive Pulmonary Disease (COPD) Management Under a Tiered Medical System in China. *Int J COPD*. 2022;17(12):181–94.

69. Hariyanti D. Pola Distribusi Penderita Penyakit Paru Obstruktif Kronik Di Ruang Rawat Inap RSUD Dokter Soedarso Pontianak. Tanjung Pura Univ Press. 2013;9–25.
70. Tabar NA, Alshraideh JA. Correlates and Predictors of Health-Related Quality of Life among Patients with COPD: An Integrative Review. *Sci Res an Acad Publ.* 2019;9(12):5–18.
71. Imaizumi Y, Eguchi K, Kario K. Lung Disease and Hypertension. *Pulse.* 2014;2(1–4):103–12.
72. Raheison C, Girodet PO. Epidemiology of COPD. *Eur Respir Rev.* 2009;18(114):213–21.
73. Barnes PJ. Sex Differences in Chronic Obstructive Pulmonary Lung Function. *Am J Respir Crit Care Med.* 2016;193(8):813–24.
74. Cassady SJ, Reed RM. Pulmonary hypertension in COPD: A case study and review of the literature. *Med.* 2019;55(8).
75. Muzlifa R, Mulyadi M, Husnah H. The Relation of Brinkman Index and Body Mass Index with Spirometry Result of Chronic Obstructive Pulmonary Disease (COPD) Outpatients in the Pulmonology and Respiratory Medicine Department of Zainoel Abidin General Hospital. *World Nutr J.* 2022;5(11):1–7.
76. Nugraha I. Hubungan Derajat Berat Merokok Berdasarkan Indeks Brinkman Dengan Derajat Berat PPOK. *Akper Patria Husada Surakarta.* 2013;53(9):1689–99.
77. Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, et al. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. *Chest.* 2006;130(1):200–6.
78. Adiana IN, Maha Putra INA. Hubungan Antara Tingkat Pendidikan Dan Komorbiditas Dengan Perilaku Perawatan Diri Pasien Penyakit Paru Obstruktif Kronis (PPOK). *J Ris Kesehat Nas.* 2023;7(1):72–7.
79. Kwon HY, Kim E. Factors contributing to quality of life in COPD patients in South Korea. *Int J COPD.* 2016;11:103–9.
80. Salawati L, Husnah H, Nawawi YS, Muchlisin ZA. Relationship between smoking activity and chronic obstructive pulmonary disease in the Zainoel Abidin General Hospital, Banda Aceh, Indonesia. *Open Access Maced J Med Sci.* 2020;8(11):705–7.
81. Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, et al. Smoking duration, respiratory symptoms, and COPD in adults aged >45 years with a smoking history. *Int J COPD.* 2015;10:1409–16.
82. Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: Cellular and molecular mechanisms. *J Dent Res.* 2012;91(2):142–9.

83. Rima A, Surad. Korelasi Antara Jumlah Makrofag, Neutrofil dan Kadar Enzim Matrix Metalloproteinase pada Cairan Kurasan Bronkial Perokok. 2007;27(3):143–4.
84. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, et al. Do GOLD stages of COPD severity really correspond to differences in health status? *Eur Respir J*. 2003;22(3):444–9.
85. Jaswirna AA, Irasanti SN, Ibnusantosa G. Hubungan perilaku merokok dan komorbid dengan lama rawat inap pasien PPOK di RSUD Al Ihsan Bandung tahun 2019-2021. *Bandung Conf Ser Med Sci* [Internet]. 2023;3(1):84–90. Available from: <https://doi.org/10.29313/bcsms.v3i1.5678>
86. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. *Chest*. 2007 Jan;131(1):94–100.
87. Zhang L, Liu Y, Zhao S, Wang Z, Zhang M, Zhang S, et al. The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis. *Int J COPD*. 2022;17(4):1365–79.
88. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. *Circ Heart Fail*. 2011;4(3):257–65.
89. Luca E, Bodrug N. The frequency of pulmonary hypertension in chronic obstructive pulmonary disease of geriatric patients: a narrative literature review. *Egypt J Intern Med*. 2022;34(1):11–7.
90. Basak S, Mukherjee R, Chowdhury S, Roy S, Banerjee R, Bhattacharya R. Evaluation of Cardiac function in COPD patients and correlation with disease severity: A cross sectional study. *Asian J Med Sci*. 2021;12(3):14–9.
91. Humbert M, Sitbon O, Yaïci A, Montani D, O’Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. *Eur Respir J*. 2010;36(3):549–55.
92. Lee WTN, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. *Eur Respir J*. 2012;40(3):604–11.
93. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: Insights from the Spanish registry. *Eur Respir J*. 2012;40(3):596–603.
94. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. *Eur Respir J*. 2014;43(2):523–30.
95. Rodriguez-Arias JJ, García-Álvarez A. Sex Differences in Pulmonary Hypertension. *Front Aging*. 2021;2(10):1–11.
96. Takase T, Taniguchi M, Hirano Y, Nakazawa G, Miyazaki S, Iwanaga Y.

Sex difference in pulmonary hypertension in the evaluation by exercise echocardiography. *Pulm Circ.* 2021;11(1):5–11.

97. Lutter JI, Jörres RA, Welte T, Watz H, Waschki B, Alter P, et al. Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort. *Int J Chron Obstruct Pulmon Dis.* 2020;15:2787–98.
98. Mohammed Y, ElShahid GS, Osman NM, ElHameed NQA. Cardiac evaluation of patients with chronic obstructive pulmonary disease using echocardiography. *Egypt J Bronchol.* 2019;13(1):12–5.
99. Jain S, Jain A, Khoja AM. Effect of Smoking Observational Study on Pulmonary Hypertension : Prospective. 2019;6691:2335–8.
100. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J.* 2009;33(5):1165–85.
101. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. *Eur Respir J.* 2003;21(5):892–905.
102. Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease. *Respir Investig.* 2016;54(6):387–96.
103. dos Santos NC, Miravittles M, Camelier AA, de Almeida VDC, Tosta Maciel RRB, Rosa Camelier FW. Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review. *Tuberc Respir Dis (Seoul).* 2022;85(3):205–20.
104. Raherison C, Ouaalaya EH, Bernady A, Casteigt J, Nocent-Eijnani C, Falque L, et al. Comorbidities and COPD severity in a clinic-based cohort. *BMC Pulm Med.* 2018;18(1):1–10.
105. Pan M, Han Y, Si R, Guo R, Desai A, Makino A. Hypoxia-induced pulmonary hypertension in type 2 diabetic mice. *Pulm Circ.* 2017;7(1):175–85.
106. Moral-Sanz J, Lopez-Lopez JG, Menendez C, Moreno E, Barreira B, Morales-Cano D, et al. Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats. *Exp Physiol.* 2012;97(5):676–86.
107. Hansmann G, Wagner RA, Schellong S, Perez VADJ, Urashima T, Wang L, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor- γ activation. *Circulation.* 2007;115(10):1275–84.
108. Green DE, Murphy TC, Kang BY, Searles CD, Hart CM. PPAR γ Ligands Attenuate Hypoxia-Induced Proliferation in Human Pulmonary Artery Smooth Muscle Cells through Modulation of MicroRNA-21. *PLoS One.* 2015;10(7):133–5.

109. Gupta NK, Agrawal RK, Srivastav AB, Ved ML. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. *Lung India*. 2011;28(2):105–9.
110. Livesay J, Fogelson B, Tahir H, Baljepally R. Comparison of Tricuspid Regurgitation Severity Between Cardiac Resynchronization Therapy Versus Right Ventricular Pacing in Patients With Chronic Obstructive Pulmonary Disease. *Cardiol Res*. 2022;13(3):128–34.
111. Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population. *COPD*. 2017 Oct;14(5):484–9.
112. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. *Eur Respir J*. 2019 Jan;53(1).

